HGEN News and Press, Humanigen Inc. From 01/27/21

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study PR Newswire SAN DIEGO and BURLINGAME, Calif. , Jan. 27, 2021 /PRNewswir...

CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patients with COVID-19. Despite monoclonal antibody drug approvals for 88 chronic inflammatory ...

Emergent BioSolutions (EBS) and Humanigen (HGEN) have entered into a contract development and manufacturing ((CDMO)) services agreement to accelerate the drug product manufacturing of lenzilumab, to prevent and treat an immune hyper-response called “cytokine storm.”Emergent...

Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab™, an an...

Adamis Pharmaceuticals (ADMP) +66% as its epinephrine products added to Walgreens club.Climate Change Crisis Real Impact I Acquisition Corporation (CLII) +48% as EV fast charging company EVgo to go public via SPAC.SCYNEXIS (SCYX) +36%.Humanigen (HGEN) +20% on expanding partners...

Humanigen (HGEN) soars 8% premarket after expanding its Cooperative Research and Development Agreement ((CRADA)) that the company had previously inked with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, ...

The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) and the Biomedical Advanced Research and Development Authority (BARDA) supports the development of lenzilumab as a potential treatment for patients with COVID-19 Humanigen, ...

Shares of Humanigen (NASDAQ: HGEN) were down by 8.6% as of 12:50 p.m. EST Wednesday, after having fallen by as much as 13% earlier in the trading day. The catalyst for these losses seems to be an update the clinical-stage biopharmaceutical company delivered regarding its phase 3 cli...

Jefferies sees Humanigen ([[HGEN]] -11.2%) drop as a 'buying opportunity', as the stock plunges on protocol update of its late-stage COVID-19 study's main objective, evaluating lenzilumab. The company has switched to a more challenging primary endpoint, ventilator-free survival, pre...

Humanigen (HGEN) fell 6% in premarket on low volume after changing the trial protocol of Phase 3 trial evaluating lenzilumab, an experimental medicine for COVID-19.More details to follow. For further details see: Humanigen `panic selling' is a buying opport...